Protagonist Announces Appointment of Newman Yeilding, M.D. as Chief Scientific Advisor
Protagonist Therapeutics (NASDAQ:PTGX) has appointed Newman Yeilding, M.D. as Chief Scientific Advisor, effective August 1, 2024. Dr. Yeilding, an accomplished physician-scientist with expertise in inflammatory and immunologic diseases, joins from Janssen Pharmaceutical Companies of Johnson & Johnson. He brings 17 years of experience in R&D and commercialization of novel therapeutics in the I&I space.
As Chief Science Advisor, Dr. Yeilding will provide leadership in discovery, pre-clinical, and translational research to maximize the impact of Protagonist's peptide platform. His appointment aligns with the company's goal to expand its pipeline with drug candidates having blockbuster potential, including the oral peptide IL-17 antagonist program.
Protagonist Therapeutics (NASDAQ:PTGX) ha nominato Newman Yeilding, M.D. come Chief Scientific Advisor, a partire dal 1 agosto 2024. Il Dr. Yeilding, un medico-scienziato esperto in malattie infiammatorie e immunologiche, arriva dalle aziende farmaceutiche Janssen di Johnson & Johnson. Porta con sé 17 anni di esperienza nella R&S e commercializzazione di nuove terapie nell'area I&I.
Come Chief Science Advisor, il Dr. Yeilding fornirà leadership nella scoperta, nella ricerca preclinica e tradotta per massimizzare l'impatto della piattaforma peptidica di Protagonist. La sua nomina è in linea con l'obiettivo dell'azienda di espandere il proprio portafoglio con candidati farmacologici con un potenziale di successo straordinario, incluso il programma per l'antagonista peptidico IL-17 orale.
Protagonist Therapeutics (NASDAQ:PTGX) ha nombrado a Newman Yeilding, M.D. como Asesor Científico Principal, a partir del 1 de agosto de 2024. El Dr. Yeilding, un médico-científico destacado con experiencia en enfermedades inflamatorias e inmunológicas, proviene de las empresas farmacéuticas Janssen de Johnson & Johnson. Aporta 17 años de experiencia en I+D y comercialización de nuevas terapias en el ámbito de I&I.
Como Asesor Científico Principal, el Dr. Yeilding proporcionará liderazgo en la investigación de descubrimiento, preclínica y translacional para maximizar el impacto de la plataforma de péptidos de Protagonist. Su nombramiento se alinea con el objetivo de la empresa de expandir su cartera con candidatos a fármacos con potencial de éxito rotundo, incluido el programa de antagonistas de péptidos IL-17 orales.
Protagonist Therapeutics (NASDAQ:PTGX)는 Newman Yeilding, M.D.를 최고 과학 고문으로 임명했습니다. 임기는 2024년 8월 1일부터 시작됩니다. Yeilding 박사는 염증 및 면역 질환에 대한 전문 지식을 가진 뛰어난 의사-과학자로, Johnson & Johnson의 Janssen 제약 회사에서 합류합니다. 그는 I&I 영역에서 새로운 치료제의 연구 개발 및 상용화 분야에서 17년의 경력을 가지고 있습니다.
최고 과학 고문으로서 Yeilding 박사는 Protagonist의 펩타이드 플랫폼의 영향을 극대화하기 위해 발견, 전임상 및 번역 연구에서 리더십을 제공할 것입니다. 그의 임명은 대박 잠재력을 지닌 약물 후보들로 파이프라인을 확장하는 회사의 목표와 일치합니다. 여기에는 경구 펩타이드 IL-17 길항제 프로그램이 포함됩니다.
Protagonist Therapeutics (NASDAQ:PTGX) a nommé Newman Yeilding, M.D. en tant que Conseiller Scientifique Principal, à compter du 1er août 2024. Le Dr Yeilding, un médecin-scientifique accompli ayant une expertise dans les maladies inflammatoires et immunologiques, rejoint l'entreprise après avoir exercé chez Janssen Pharmaceutical Companies de Johnson & Johnson. Il apporte avec lui 17 ans d'expérience dans la recherche et développement et la commercialisation de nouvelles thérapies dans le domaine I&I.
En tant que Conseiller Scientifique Principal, le Dr Yeilding fournira un leadership dans la découverte, la recherche préclinique et la recherche translationnelle afin de maximiser l'impact de la plateforme peptidique de Protagonist. Sa nomination s'inscrit dans l'objectif de l'entreprise d'élargir son portefeuille avec des candidats-médicaments ayant un potentiel de succès retentissant, y compris le programme d'antagonistes peptidiques IL-17 oraux.
Protagonist Therapeutics (NASDAQ:PTGX) hat Newman Yeilding, M.D. zum Chief Scientific Advisor ernannt, der am 1. August 2024 seine Tätigkeit aufnehmen wird. Dr. Yeilding, ein erfolgreicher Arzt-Wissenschaftler mit Expertise in entzündlichen und immunologischen Erkrankungen, wechselt von den Janssen Pharmaceutical Companies von Johnson & Johnson. Er bringt 17 Jahre Erfahrung in der Forschung und Entwicklung sowie der Kommerzialisierung neuartiger Therapeutika im Bereich I&I mit.
In seiner Rolle als Chief Science Advisor wird Dr. Yeilding die Leitung in der Entdeckung, der präklinischen und translationalen Forschung übernehmen, um den Einfluss der Peptidplattform von Protagonist zu maximieren. Seine Ernennung steht im Einklang mit dem Ziel des Unternehmens, sein Portfolio mit Medikamentenkandidaten mit Blockbuster-Potenzial auszubauen, einschließlich des Programms für orale IL-17-Antagonisten.
- Appointment of experienced physician-scientist as Chief Scientific Advisor
- Addition of expertise in inflammatory and immunologic diseases
- Potential for expansion of pipeline with blockbuster drug candidates
- Enhancement of R&D capabilities in peptide therapeutics
- None.
Dr. Yeilding joins Protagonist from Janssen Pharmaceutical Companies of Johnson & Johnson, where he held leadership roles in the immunology therapeutic area, bringing extensive experience in R&D and commercialization of novel therapeutics in the I&I space
NEWARK, CA / ACCESSWIRE / July 31, 2024 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced the appointment of Newman Yeilding, M.D. to the role of Chief Scientific Advisor, effective August 1, 2024. Dr. Yeilding is an accomplished physician-scientist with deep knowledge and expertise in inflammatory, rheumatology, autoimmune and immunologic diseases. As Chief Science Advisor, he will provide discovery, pre-clinical and translational research and development leadership to maximize the impact of the Protagonist platform in areas where peptides have the ability to be best-in-class therapeutics.
"We are very pleased to welcome Dr. Yeilding to Protagonist as our full-time Chief Scientific Advisor," said Dinesh V. Patel, Ph.D., President and Chief Executive Officer of Protagonist. "With extensive experience in research, development, and commercialization of novel therapeutics in the I&I space, Newman will be a great addition to the Protagonist R&D team as we expand our pipeline over the short- and long-term with drug candidates with blockbuster potential, including the oral peptide IL-17 antagonist program."
"I am delighted to be joining the Protagonist team," said Dr. Yeilding. "Peptide therapeutics have the ability to be significantly more effective than small molecule or antibody-based drugs for many serious and life-threatening diseases. I look forward to working with the Protagonist team to maximize the impact of the company's peptide technology platform and continue bringing meaningful therapeutic innovations out of the lab and into clinical practice and patient care."
Dr. Yeilding joins Protagonist following his 17-year career at Janssen, where he held a number of senior roles including Head of Immunology Development and R&D, Vice President of Immunology Dermatology, GI Development Senior Director, Vice President Immunology, and STELARA and Early Development Compound Development Team Leader. During his time at Janssen, he provided scientific and management leadership of immunology development initiatives in clinical departments including Rheumatology, Gastroenterology, Dermatology, and Pediatric Development. He led an R&D organization of approximately 250 members in close collaboration with the Immunology Global Strategic Commercial Organization to accelerate development, commercialization, and market access of innovative first-in-class or best-in-class compounds for the global Immunology market. Prior to Janssen, he was the Associate Director of Medical Affairs at Centocor and served as Chief of Hematology-Oncology at the Philadelphia Veterans Administration Medical Center, after spending four years as a research track faculty with research focused on tumor angiogenesis. Dr. Yeilding earned his M.D. from the University of Alabama, Birmingham, and a B.S. from Davidson University in North Carolina.
About Protagonist
Protagonist Therapeutics is a biopharmaceutical company with peptide-based new chemical entities (NCEs) rusfertide and JNJ-2113 (formerly PN-235) in advanced Phase 3 stages of clinical development, both derived from the Company's proprietary technology platform. Protagonist and Johnson & Johnson (JNJ) scientists jointly discovered PN-235 as part of Protagonist's Interleukin-23 receptor (IL-23R) antagonist collaboration with JNJ and followed it through IND-enabling pre-clinical and Phase 1 studies, with JNJ assuming responsibility for further clinical development. Rusfertide, a mimetic of the natural hormone hepcidin, is the Company's lead drug candidate currently in a global Phase 3 development program for polycythemia vera (PV). The randomized portion of the Phase 2 REVIVE study has been successfully completed, and results were published in the New England Journal of Medicine in February 2024. The 1-year open-label extension (OLE) component of Phase 2 REVIVE is ongoing, followed by an additional 2-year long-term extension (LTE) THRIVE study. Enrollment has been completed in the global Phase 3 VERIFY study of rusfertide in polycythemia vera. Rusfertide is being co-developed and co-commercialized with Takeda pursuant to a worldwide collaboration and license agreement with Takeda announced in January 2024.
More information on Protagonist and its pipeline drug candidates and clinical studies can be found on the Company's website at www.protagonist-inc.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the potential benefits of JNJ-2113 and rusfertide, the timing of JNJ-2113 and rusfertide clinical trials, and timing of developments in our discovery programs. In some cases, you can identify these statements by forward-looking words such as "anticipate," "believe," "may," "will," "expect," or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our ability to develop and commercialize our product candidates, our ability to earn milestone payments under our collaboration agreements with Janssen and Takeda, our ability to use and expand our programs to build a pipeline of product candidates, our ability to obtain and maintain regulatory approval of our product candidates, our ability to operate in a competitive industry and compete successfully against competitors that have greater resources than we do, and our ability to obtain and adequately protect intellectual property rights for our product candidates. Additional information concerning these and other risk factors affecting our business can be found in our periodic filings with the Securities and Exchange Commission, including under the heading "Risk Factors" contained in our most recently filed periodic reports on Form 10-K and Form 10-Q filed with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release.
Investor Relations Contact
Corey Davis, Ph.D.
LifeSci Advisors
cdavis@lifesciadvisors.com
+1 212 915 2577
Media Relations Contact
Virginia Amann
ENTENTE Network of Companies
virginiaamann@ententeinc.com
+1 833 500 0061
SOURCE: Protagonist Therapeutics, Inc.
View the original press release on accesswire.com
FAQ
Who is Newman Yeilding, M.D., and what is his new role at Protagonist Therapeutics (PTGX)?
What is Dr. Yeilding's background before joining Protagonist Therapeutics (PTGX)?
How might Dr. Yeilding's appointment impact Protagonist Therapeutics' (PTGX) future developments?
What specific areas of expertise does Dr. Yeilding bring to Protagonist Therapeutics (PTGX)?
